ADJUVANT CHEMOTHERAPY OF CIS-DIAMMINEDICHLOROPLATINUM, ADRIAMYCIN AND 5-FLUOROURACIL FOR UROTHELIAL CANCERS

Twenty-two patients with urothelial cancers who received radical operations from April 1984 to December 1986 were studied. The patients received adjuvant chemotherapy after the operations with two regimens : regimen 1 (CA) consisted of 15-20 mg/m2 cis-diamminedichloroplatinum (CDDP) on days 1-5, 30 mg/m2 adriamycin (ADM) on day 2 ; regimen 2 (CAF) consisted of 15-20 mg/m2 CDDP on days 1-5, 30 mg/m2 ADM on day 5, 250 mg/day 5-fluorouracil on days 1-10. The two regimens were repeated more than once. After adjuvant therapy, the maintenance therapy used was UFT, 3 tablets/day orally.Twenty-two patients were followed for a mean of 18.5 months. The over-all 1 and 2-year actuarial survival rate was 89.8%. The survival rates of badder cancer patients with adjuvant chemotherapy were improved with non-adjuvant chemotherapy, as reported previously. None of patients with renal pelvic or ureter tumor died. Tumor recurrences were observed at local sites in 1 patient, in the lung in 1 patient and in subcutaneous tissue in 1 patient. Myelosuppression and vomiting occurred but the degrees were minimal.Adjuvant chemotherapy with CA and CAF regimens were effective for urothelial cancers.